Table 2.

Summary of different OTC/POMs and routes of administration used by respondents in the preceding month.

	Route of administration			Oral	Inject	Snort	Not stated	Total
OTC/POM reported as being misused	Antidepressants	Amitriptyline		1	0	0	1	2 (1.7%)
		Mirtazapine		3	0	0	0	3 (2.6%)
	Anabolic steroids (eg, testosterone)			1	0	0	0	1 (0.9%)
	Antihistamine			3	0	0	0	3 (2.6%)
	Baclofen			1	0	0	0	1 (0.9%)
	Hypnotics	Benzodiazepines		26	0	0	0	26 (22.2%)
		Zopiclone		6	0	0	1	7 (6.0%)
	Gabapentinoids		Gabapentin	3	1	0	1	5 (4.3%)
			Pregabalin	14	0	0	3	17 (14.5%)
	Opioids	Buprenorphine		2	0	0	0	2 (1.7%)
		Codeine	Non-combination product	9	0	0	7	16 (13.7%)
			Combination product	13	0	0	7	20 (17.1%)
		Fentanyl		0	1	0	0	1 (0.9%)
		Dihydrocodeine		1	0	0	0	1 (0.9%)
		Methadone		4	0	0	0	4 (3.4%)
		Morphine		1	1	0	0	2 (1.7%)
		Tramadol		3	0	1	0	4 (3.4%)
	Quetiapine			2	0	0	0	2 (1.7%)
Total				93 (79.5%)	3 (2.6%)	1 (0.9%)	20 (17.1%)	117